Results 41 to 50 of about 4,006,149 (207)

IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII [PDF]

, 2015
The development of inhibitory antibodies to factor VIII (FVIII) is a major obstacle in using this clotting factor to treat individuals with hemophilia A. Patients with a congenital absence of FVIII do not develop central tolerance to FVIII, and therefore,
Emanuela Marchesini, Santagostino, Elena, IANNITTI, ROSSANA GIULIETTA, Marchesini, Emanuela, Iannitti, Rossana, Matteo Pirro, Volpi, Claudia, Alfonso Iorio, SANTORO, Cristina, Talesa, Vincenzo N., Boon, Louis, Chiappalupi, Sara, Rossana Iannitti, Di Minno, Matteo N. D, Mancuso, Maria E, Matteo N.D. Di Minno, Giuseppe Tagariello, Orabona, Ciriana, Carmine Vacca, Morfini, Massimo, Vincenzo N. Talesa, Sara Chiappalupi, Louis Boon, Paolo Radossi, Raffaele Landolfi, Coppola, Antonio, Puccetti, Paolo, Ciriana Orabona, Antonio Coppola, Elena Santagostino, Di Minno, Matteo N. D., Di Minno, Giovanni, Fallarino, Francesca, Vacca, Carmine, Tagariello, Giuseppe, Claudia Volpi, Pirro, Matteo, Mazzucconi, Maria G., DI MINNO, matteo nicola dario, Guglielmo Sorci, Angiola Rocino, Marco Gargaro, Mazzucconi, Maria G, Gargaro, Marco, TALESA, Vincenzo Nicola, Maria E. Mancuso, Maria G. Mazzucconi, Grohmann, Ursula, Rocino, Angiola, Matino, Davide, Ursula Grohmann, Dietmar Fuchs, Giancarlo Castaman, Antonella Tosti, Giovanni Di Minno, MAZZUCCONI, Maria Gabriella, Radossi, Paolo, Belvini, Donata, Davide Matino, Castaman, Giancarlo, Mancuso, Maria E., Donata Belvini, Francesca Fallarino, Cristina Santoro, Paolo Puccetti, Sorci, Guglielmo, Massimo Morfini, Landolfi, Raffaele, Tosti, Antonella, Fuchs, Dietmar, Iorio, Alfonso   +70 more
core   +1 more source

Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy

, 2021
Indoleamine 2,3-dioxygenase-1 (IDO1) plays an important role in tumor immune escape. However, unsatisfactory clinical efficacies of selective IDO1 inhibitors have impeded their further development, suggesting that they do not exert sufficient antitumor ...
Zhaoxing Chu (7536365), Jinxi Shan (11784280), Hui Shen (66625), Shan Zhang (431282), Yi Zou (439002), Yiran Ge (8194932), Zhifeng Wei (11453658), Huanhuan Wu (339728), Junjie Wang (172690), Kewen Peng (8194929), Xin He (48101), Qihua Zhu (1555147), Guangchao He (8194926), Yungen Xu (1434802)   +13 more
core   +3 more sources

ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS [PDF]

Neuro Oncol, 2017
Reardon D, Desjardins A, Rixe O, Cloughesy T, Alekar S, Gamelin E, Williams J, Meissen J, Taylor C, Lassman A.   +9 more
europepmc   +2 more sources

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy [PDF]

, 2018
Tumors use indoleamine 2,3-dioxygenase-1 (IDO1) as a major mechanism to induce an immunosuppressive microenvironment. IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies.
Gomes, Bruno, Tumang, J, Marillier, Reece, Bartlett, Derek, Driessens, G, Rabolli, Virginie, Wythes, M, Van den Eynde, Benoit J, Dillon, Christopher P, Tumang, Joseph, Gomes, B, Fantin, VR, Pirson, R, Fantin, Valeria R., van den Eynde, BJ, Cai, D, Dalvie, Deepak, Van den Eynde, Benoît, Dillon, CP, Bartlett, D, Crosignani, S, Kraus, M, Streiner, N, Torti, Vince R, Zheng, Xianxian, Denies, S, Tsaparikos, Konstantinos, Torti, Vince R., Maegley, KA, Cauwenberghs, Sandra, Kraus, Manfred, Yao, L-C, Dillon, Christopher P., Letellier, M-C, Cai, Danying, Crosignani, Stefano, Zheng, X, Rabolli, V, Driessens, Gregory, Guo, J, Pirson, Romain, Dalvie, D, Marillier, R, Ray, Chad, Guo, Jie, Miller, Nichol, Cauwenberghs, S, Letellier, Marie-Claire, Denies, Sofie, Wythes, Martin, Tsaparikos, K, Li, Wenlin, Fantin, Valeria R, Miller, N, Yao, Li-Chin, Streiner, Nicole, Torti, VR, Li, W, Maegley, Karen, Ray, C   +59 more
core   +1 more source

IDO1 mRNA upregulation was associated with gene body hypermethylation and poor overall survival in esophageal squamous cell carcinoma

, 2021
Introduction This study aimed to explore the potential genetic and epigenetic mechanisms associated with IDO1 mRNA dysregulation in esophageal cancer (ESCA).
Chang-Qing Zhang, Guo-Ying Miao, Wen Ma, Xue-Bin Wang, Rong Wang, Shu-Ping Li   +5 more
core   +1 more source

Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation

Frontiers in Immunology, 2022
The indoleamine 2,3-dioxygenase 1 (IDO1) metabolic circuitry, comprising the first tryptophan (Trp) catabolite L-kynurenine (Kyn) and the aryl hydrocarbon receptor (AHR), has emerged as a mechanism of cancer immune evasion.
Claudio Giacinto Atene, Stefania Fiorcari, Nicolò Mesini, Silvia Alboni, Silvia Alboni, Silvia Martinelli, Silvia Martinelli, Monica Maccaferri, Giovanna Leonardi, Leonardo Potenza, Leonardo Potenza, Mario Luppi, Mario Luppi, Rossana Maffei, Roberto Marasca, Roberto Marasca   +15 more
doaj   +1 more source

Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy

Molecular Therapy: Methods & Clinical Development, 2021
We investigated the immunogenic cell death provoked by oxaliplatin (OXA) and the involvement of OXA-induced immunosuppression in colorectal cancer. Immune-proficient or -deficient mice were employed to evaluate the therapeutic effects of OXA. Immunogenic
Xiaofei Miao, Ye Zhang, Zengyao Li, Longchang Huang, Taojian Xin, Renhui Shen, Tong Wang   +6 more
doaj   +1 more source

Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2

Pharmaceuticals, 2022
Indoleamine 2, 3-dioxygenase 1 (IDO1) is commonly expressed by cancers as a mechanism for evading the immune system. Preclinical and clinical studies have indicated the potential of combining IDO1 inhibitors with immune therapies for the treatment of ...
Sofian M Tijono, Brian D. Palmer, Petr Tomek, Jack U. Flanagan, Kimiora Henare, Swarna Gamage, Lukas Braun, Lai-Ming Ching   +7 more
doaj   +1 more source

Macrophage‐derived Extracellular Vesicles Disguised AIEgen/IDO1 Inhibitor Nanoplatform Reactivate “Immune‐Hot” for Photothermal Immunotherapy via Multi‐Dimensionally Reprograms Tumor Microenvironment

Aggregate
Reversing the tumor microenvironment (TME) from “cold” to “hot” tumor represents a pivotal strategy to overcome the clinical bottleneck of poor response rates to immunotherapy in solid tumors.
Xue Li, Xiang-Long Zhao, Yin Zhou, Yu Liu, Yushuo Feng, Ye-Neng Dai, Ping Gong, Qi Zhao, Ming Dong   +8 more
semanticscholar   +1 more source

The list of published IDO1 inhibitor.

, 2014
The list of published IDO1 inhibitor.
Yasuko Yamamoto (522533), Shinjiro Imai (512471), Ryuta Fukutomi (522534), Yushi Matuo (522537), Kuniaki Saito (9421), Yoshio Ozawa (522535), Masako Abe (522536), Rie Yamamoto (522532)   +7 more
core   +1 more source